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ABSTRACT
Human cytomegalovirus (HCMV) counteracts host defenses that otherwise act to limit viral protein synthesis. One such defense
is the antiviral kinase protein kinase R (PKR), which inactivates the eukaryotic initiation factor 2 (eIF2) translation initiation
factor upon binding to viral double-stranded RNAs. Previously, the viral TRS1 and IRS1 proteins were found to antagonize the
antiviral kinase PKR outside the context of HCMV infection, and the expression of either pTRS1 or pIRS1 was shown to be nec-
essary for HCMV replication. In this study, we found that expression of either pTRS1 or pIRS1 is necessary to prevent PKR acti-
vation during HCMV infection and that antagonism of PKR is critical for efficient viral replication. Consistent with a previous
study, we observed decreased overall levels of protein synthesis, reduced viral protein expression, and diminished virus replica-
tion in the absence of both pTRS1 and pIRS1. In addition, both PKR and eIF2were phosphorylated during infection when
pTRS1 and pIRS1 were absent. We also found that expression of pTRS1 was both necessary and sufficient to prevent stress gran-
ule formation in response to eIF2 phosphorylation. Depletion of PKR prevented eIF2 phosphorylation, rescued HCMV repli-
cation and protein synthesis, and reversed the accumulation of stress granules in infected cells. Infection with an HCMVmutant
lacking the pTRS1 PKR binding domain resulted in PKR activation, suggesting that pTRS1 inhibits PKR through a direct inter-
action. Together our results show that antagonism of PKR by HCMV pTRS1 and pIRS1 is critical for viral protein expression and
efficient HCMV replication.
IMPORTANCE
To successfully replicate, viruses must counteract host defenses that limit viral protein synthesis. We have identified inhibition
of the antiviral kinase PKR by the viral proteins TRS1 and IRS1 and shown that this is a critical step in HCMV replication. Our
results suggest that inhibiting pTRS1 and pIRS1 function or restoring PKR activity during infectionmay be a successful strategy
to limit HCMV disease.
Human cytomegalovirus (HCMV), like all viruses, requireshost ribosomes and translation factors for the synthesis of
viral proteins. Consequently, upon sensing infection, host antivi-
ral defenses inactivate critical translation factors, leading to re-
duced viral replication. To circumvent these defenses, HCMV
manipulates antiviral signaling pathways to allow for efficient viral
protein synthesis. Thus, the interface of HCMV with the host
translation machinery lies at the front line of the battle between
host and virus for control of the infected cell.
Perhaps the best-studied antiviral defense targeting viral
mRNA translation is the RNA-dependent protein kinase R (PKR).
PKR binds to double-stranded RNAs (dsRNAs) produced during
viral infections, resulting in PKR dimerization and activating au-
tophosphorylation (1–4). Activated PKR in turn inhibits mRNA
translation by phosphorylating its substrate the eukaryotic initia-
tion factor 2 alpha (eIF2) (5–8). eIF2 plays a critical role in
translation initiation as a regulatory subunit of the trimeric eIF2
complex, whichmediates binding of the ternary complex, consist-
ing of eIF2, GTP, and tRNAMet, to the ribosome (9). eIF2 phos-
phorylation by PKR prevents recycling of the ternary complex
after initiation, resulting in an overall decrease in translation ini-
tiation and diminished viral protein synthesis and replication
(10).
Phosphorylation of eIF2 further limits protein synthesis by
sequestering actively translatingmRNAs into cytoplasmic ribonu-
cleoprotein complexes called stress granules (11). During viral
infection, stress granules aremost often induced by activatedPKR;
however, additional virus-induced stressors such as the accumu-
lation of unfolded proteins and/or nutrient depletion are also in-
volved (12). Prolonged periods of stress lead to the degradation of
stress granule-associated mRNAs, which further inhibits viral
protein expression (13). Despite the induction of stress response
pathways known to trigger stress granule formation, stress gran-
ules do not form in HCMV-infected cells (14, 15). This suggests
that HCMV encodes viral proteins that inhibit stress granule for-
mation. However, a role for HCMV proteins in the inhibition of
stress granule formation has not been described.
Many viruses generate dsRNA ligands recognized by PKR dur-
ing infection, and thus viruses commonly encode PKR antago-
nists. Human cytomegalovirus encodes two PKR antagonists, the
TRS1 and IRS1 proteins (pTRS1 and pIRS1, respectively). The
amino-terminal 550 amino acids of pTRS1 and pIRS1 are encoded
by the short-repeat regions of the viral genome and are therefore
identical, while the remainder of pTRS1 and pIRS1 are encoded by
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the unique short segment of the genome and thus diverge. How-
ever, the unique regions of pTRS1 and pIRS1 are highly similar,
sharing approximately 50% amino acid conservation. Both pro-
teins limit PKR activation outside the context of HCMV infection
(16), and the expression of either pTRS1 or pIRS1 is necessary for
HCMV replication (17). Several functional domains have been
identified in pTRS1 and pIRS1, including an RNA binding do-
main between amino acids 86 and 246 (18) and a PKR binding
domain in the unique carboxyl terminus (19). While both do-
mains are necessary for PKR antagonism in heterologous systems
and in vitro, the contribution of each domain to PKR inhibition
during HCMV infection is currently unknown.
Efforts to study pTRS1 functions in the context of HCMV in-
fection have been complicated by the functional redundancy of
pIRS1. Expression of either protein is sufficient to supportHCMV
replication at high multiplicities of infection (MOI) (17, 20), al-
though a TRS1 deletion virus is attenuated after infection at low
MOI (20). However, deletion of both TRS1 and IRS1 results in a
replication-deficient virus. As a result, the majority of studies de-
fining functional roles for pTRS1 and pIRS1 have been performed
in vitro or in heterologous systems outside the context of HCMV
infection. Both pTRS1 and pIRS1 complement the growth defect
of vaccinia virus mutants lacking the E3L protein (16, 18, 21–24),
a known PKR inhibitor, and pTRS1 complements the growth of
herpes simplex virus (HSV) mutants lacking the ICP34.5 protein
(25), which stimulates eIF2 dephosphorylation through the re-
cruitment of a cellular phosphatase (26, 27). Similarly, pTRS1
complements the replication of murine cytomegalovirus
(MCMV) strains lacking the PKR antagonists m142 orm143 (28,
29). While these studies show that pTRS1 and pIRS1 act as PKR
antagonists, the role of PKR in suppressingHCMV replication has
not been defined. In addition, the requirement for pTRS1 and
pIRS1 to prevent PKR activation during HCMV infection has not
been described.
A previous study by Marshall et al. (17) generated an HCMV
mutant with TRS1 and IRS1 deleted and found that in the absence
of both pTRS1 and pIRS1, eIF2 is phosphorylated and HCMV
protein synthesis and replication are dramatically inhibited.How-
ever, this study did not measure PKR activation in the absence of
both pTRS1 and pIRS1, nor was it determined if depleting PKR
could prevent eIF2 phosphorylation or restore viral protein syn-
thesis and replication. Fibroblasts express three additional eIF2
kinases, GCN2, HRI, and PERK, which phosphorylate eIF2 in
response to amino acid stress, reactive oxygen species (ROS), and
activation of the unfolded protein response (UPR), respectively
(30, 31). Several studies show that HCMV induces ROS (32–34)
and activates PERK as part of the virus-induced UPR (35, 36). In
addition,HCMVpotentially induces amino acid stress due to high
levels of ongoing host and viral protein synthesis. Consistent with
this idea, mice lacking GCN2 are more susceptible to infection
with the related murine cytomegalovirus (MCMV) (37). The role
of these additional eIF2 kinases in HCMV replication is un-
known, as is the ability of pTRS1 to regulate their activity. In
addition, pTRS1 and pIRS1 have other functions potentially un-
related to PKR antagonism, including suppression of autophagy
(38, 39), transactivation of gene expression (40), and packaging of
viral DNA into capsids (41). pTRS1 also interacts with the HCMV
DNA polymerase accessory subunit and promotes ori-Lyt-depen-
dent DNA replication through an unknown mechanism (42–46).
How these functions contribute to the replication defect observed
in the absence of pTRS1 and pIRS1 has not been tested.
In this study, we used a combination of short hairpin RNAs
(shRNAs) and viral mutants to evaluate the role of antagonism of
PKR by pTRS1 and pIRS1 during HCMV infection. Our results
confirm previous studies showing that either IRS1 or TRS1 is suf-
ficient for HCMV replication (17). We found that expression of
either pTRS1 or pIRS1 is both necessary and sufficient to suppress
PKR activation and eIF2 phosphorylation and maintain overall
levels of protein synthesis inHCMV-infected cells. In addition, we
found that expression of either pTRS1 or pIRS1 is necessary to
prevent stress granule formation duringHCMV infection and that
pTRS1 alone is sufficient to prevent stress granule formation in
transfected cells. Using a pTRS1 mutant lacking a portion of the
unique carboxyl terminus, we found that the pTRS1 PKR binding
domain is necessary to prevent PKR activation during HCMV
infection. Depletion of PKR restored virus replication and viral
protein synthesis in the absence of pTRS1 and pIRS1 and pre-
vented stress granule formation. Thus, our findings demonstrate
that antagonism of PKR by pTRS1 and pIRS1 is critical for effi-
cient HCMV protein expression and replication.
MATERIALS AND METHODS
Viruses, cells, and reagents. MRC-5 fibroblasts, human foreskin fibro-
blasts (HFFs), and HeLa cells were grown in Dulbecco’s modified Eagle
medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and
100 U/ml penicillin-streptomycin. MRC-5 fibroblasts and HFFs were
used between passages 8 and 20. HCMV strain AD169 lacking the TRS1
open reading frame (ORF) was a generous gift of Adam Geballe (Univer-
sity ofWashington) and has been described previously (17). Allmutations
in the HCMV genome were generated in the AD169BADinGFP bacterial
artificial chromosome (BAC) using recombineering in Escherichia coli
strain DY380 as previously described (47, 48). To generate the PKR bind-
ing domain deletion mutant (HCMVPBD), a FLAG-FRT-KAN-FRT
cassette was PCR amplified using primers FRT FWD (5= TTAGATTATA
AAGATGATGATGATAAA 3=) and PBDFRT REV (5= TCCCCGGAGAA
GATTCCTGGTACGACTTGGACGAGACTTTCTGGGTTCTTTTAGA
TTATAAAGATGATGATGATAAA 3=) containing 50 nucleotides of ho-
mology flanking the insertion site at nucleotide 228885 (corresponding to
amino acid 679; GenBank accession number FJ527563.1). Following re-
combination, expression of the Flp recombinase was induced with arabi-
nose to excise the kanamycin cassette. The resulting recombinant contains
a FLAG epitope tag followed by a translation stop codon in framewith the
3= end of the TRS1 ORF. The gross integrity of the recombinant viral
genomes was confirmed by restriction digest, and the sequences of the
entire TRS1 open reading frame and the flanking 500 nucleotides were
confirmed by Sanger sequencing. For each mutant, two independent re-
combinants were isolated, sequenced, and characterized to control for
potential spurious mutations introduced during recombination. BAC
DNAwas purified using the NucleobondMidiprep kit (Macherey-Nagel)
according to themanufacturer’s directions. Onemicrogram of BACDNA
together with onemicrogram of pCGNpp71 (49) was electroporated into
MRC-5fibroblasts to reconstitute infectious virus. Viral stockswere prop-
agated on MRC-5 fibroblasts, and their titers were determined using the
tissue culture infective dose (TCID50)method.Unless otherwise noted, all
infections were performed at a multiplicity of infection of 1 in 300 l of
medium. The amount of cell-free virus in the supernatant was quantified
by the TCID50method onMRC-5 fibroblasts as previously described (50).
The plasmid pcDNA-pTRS1 expressing the TRS1 protein with a car-
boxyl-terminal 6 His epitope tag was a kind gift of Adam Geballe (18).
Cells were transfected with the indicated plasmids using polyethylenei-
mine (PEI) and analyzed at 24 h after transfection unless otherwise noted.
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siRNA- and shRNA-mediated depletion. Small interfering RNA
(siRNA) targeting the PKR transcript (Dharmacon SMARTpool ON-
TARGETplus EIF2AK2 siRNA) was transfected at a final concentration of
20 nM in 100 l Opti-MEM using 6 l Mission siRNA transfection re-
agent (Sigma). Complexes were incubated at room temperature for 15
min prior to dropwise addition to 30 to 50% confluentMRC-5 cells. Cells
were used in subsequent experiments at 72 h after transfection. Efficient
knockdown was routinely monitored by Western blotting. MRC-5 cells
stably expressing scrambled or IRS1-specific shRNAs were generated us-
ing the pSUPERretro system (Oligoengine). An shRNA hairpin (5=
GGAGTTCATGTTTCGCGAACATTCAAGAGATGTTCGCGAAA
CATGAACTCC 3=), which generates the mature shRNA (5= GGAGTTC
ATGTTTCGCGAACA 3=) targeting the unique 3= end of the IRS1 ORF
was cloned into the pSUPERretro vector. Retrovirus stocks were gener-
ated by transfecting the Phoenix packaging cell line (51) with the
pSUPERretro plasmids. Supernatants were collected at 48 h posttransfec-
tion, filtered through a 0.45-m filter, and used to transduce cells in the
presence of Polybrene (4 g/ml). Stable cell lines were obtained by selec-
tion in puromycin (1 g/ml) for at least 1 week prior to use.
Western blot analysis. Cells were collected by scraping at the indi-
cated times and frozen as dry pellets at80°C until use. Cells were lysed in
radioimmunoprecipitation assay (RIPA) buffer (50 mM Tris-HCl [pH
7.4], 150 mMNaCl, 1% NP-40, 0.25% deoxycholate, 1 mM EDTA) con-
taining protease and phosphatase inhibitors (Roche), and the protein
concentration was determined by the Bradford assay (Amresco). Equiva-
lent amounts of protein were resolved on SDS-PAGE gels and transferred
to nitrocellulose membranes (Amersham). For monoclonal antibodies,
membranes were blocked for 1 h at room temperature in 1% bovine
serum albumin (BSA) in TBS-T (50 mM Tris-HCl [pH 7.4], 150 mM
NaCl, 0.1%Tween 20) before incubationwith primary antibody in TBS-T
with 1% BSA for 1 h at room temperature or overnight at 4°C. For poly-
clonal antibodies, membranes were blocked in 1% BSA followed by incu-
bation with primary antibody overnight at 4°C in 5% BSA in TBS-T. For
Western blots using the phospho-eIF2 (Ser51) antibody, membranes
were blocked in 5%BSA in TBS-T overnight at 4°C, followed by overnight
incubation at 4°C with primary antibody diluted in TBS-T containing 5%
BSA. Antibodies to the following proteins were used in this study: IE1 (52)
(1:10,000), pUL44 (1:1,000; Virusys), pp28 (53) (1:5,000), pTRS1 (40)
(1:100), pIRS1 (40) (1:100), P99 antibody against pTRS1 and pIRS1 (17)
(1:10,000), tubulin (1:50,000; Sigma T6199), total PKR (1:1,000; Santa
Cruz sc-707), phospho-PKR (Thr446) (1:1,000; Abcam ab32036), total
eIF2 (1:1,000; catalog no. 3072; Cell Signaling), and phospho-eIF2
(Ser51) (1:1,000; catalog no. 3398; Cell Signaling).
Indirect immunofluorescence. Cells were seeded into wells contain-
ing glass coverslips. Where noted, cells were infected at a multiplicity of
infection of 0.5. At the time of harvest, coverslips were washed three times
for 5minwith 37°C phosphate-buffered saline (PBS) and then fixed in 2%
paraformaldehyde (PFA) for 15 min at 37°C. The cells were washed three
times in room temperature PBS and subsequently permeabilized with
0.1% Triton X-100. The cells were again washed three times with PBS
containing 0.2% Tween 20 (PBS-T) at room temperature and then incu-
bated overnight in blocking buffer (2% BSA in TBS-T). The cells were
stained for 1 h at room temperaturewith the following primary antibodies
diluted in blocking buffer: IE1 (1:10); pTRS1 (1:10); G3BP1 (Santa Cruz
sc-98561; 1:50). The coverslips were washed three times with PBS-T and
then incubated with fluorescent secondary antibody (Invitrogen goat
anti-mouse or rabbit; 1:500). The coverslips were again washed three
times, mounted on glass slides in VectaShield containing 4=,6-diamidino-
2-phenylindole (DAPI) to stain nuclei (Vector Laboratories), and sealed
with nail polish. Images were captured using a Zeiss 710 confocal micro-
scope with the help of the UNC Microscopy Core.
Quantification of stress granule formation. Control or PKR-defi-
cient HeLa cells were transfected with either a green fluorescent protein
(GFP) or pTRS1 expression vector. Twenty-four hours after transfection,
cells were treated with arsenite for 1 h and then processed for immuno-
fluorescence microscopy as above. Transfected cells (i.e., GFP or pTRS1
positive)were identified, and the relative fluorescence intensity of theGFP
or pTRS1 signal in each cell was quantified using ImageJ software. The
relative pTRS1 orGFP expression level in each cell was scored on a scale of
1 to 100, with 100 representing the highest observed expression. The pres-
ence of stress granules in each transfected cell was then determined by
measuring the formation of G3BP1 puncta. Transfected cells containing
two or more G3BP1 puncta were considered positive for stress granules,
while those with fewer than two puncta were considered negative. The
range of fluorescence intensity for GFP and pTRS1 was divided into quar-
tiles (1 to 25% of maximum, 26 to 50% of maximum, etc.), and the
percentage of cells containing stress granuleswithin each expression quar-
tile was calculated. A minimum of 100 GFP- or pTRS1-positive cells were
analyzed. The data are displayed as the percent transfected cells containing
stress granules within each quartile of GFP or pTRS1 expression.
Metabolic labeling of nascent proteins.Nascent proteins were meta-
bolically labeled and quantified as described previously (54). Briefly, cells
were incubated in methionine- and cysteine-free medium (Sigma) for 15
min. 35S-labeledmethionine and cysteine (125Ci; PerkinElmer EasyTag
Express LabelingMix) were added and allowed to incorporate for 30min.
Cells were then washed twice in ice-cold PBS, scraped, and collected by
centrifugation. Cell pellets were lysed in RIPA medium containing pro-
tease inhibitors (Roche), and protein concentrations were determined by
the Bradford assay (Amresco). Trichloroacetic acid (TCA) was added to a
final concentration of 20%, and precipitated proteins were captured on
glassmicrofiber filters by filtration under vacuum. The filters werewashed
twice with 20% TCA and once with 100% ethanol and allowed to air dry.
The filters were then transferred to vials containing scintillation fluid
(EcoScint), and radioactivity was quantified using a scintillation counter.
The amount of radioactivity was normalized to the protein concentration
for each sample.
RESULTS
HCMVmutant strains lacking either pTRS1 or pIRS1 replicate to
levels similar to those of wild-type virus (20, 55), while a mutant
lacking both pTRS1 and pIRS1 replicates poorly (17). Previous
studies of a pTRS1/pIRS1 double knockout virus were compli-
cated by the inability to efficiently complement virus replication
by expression of pTRS1 in trans (17). This likely reflected insuffi-
cient expression of the pTRS1 transgene or improper timing of
expression.We reasoned that the failure of the pTRS1 transgene to
fully complement the replication of a pTRS1/pIRS1 double dele-
tion virus would limit our ability to generate and study recombi-
nant viruses lacking domains of pTRS1 required for virus replica-
tion. Thus, we sought to develop a system that allowed us to
control pIRS1 expression and express pTRS1mutants towild-type
levels withwild-type kinetics from the context of the viral genome.
We therefore used a combination of viral genetics and shRNA-
mediated gene silencing to manipulate pTRS1 and pIRS1 expres-
sion during HCMV infection. We first generated primary human
fibroblasts expressing either a scrambled shRNA (control cells) or
an shRNA specific for the pIRS1 transcript (shIRS1-HFs). Infect-
ing the cells with wild-type virus allowed us to study the contribu-
tion of pTRS1 to HCMV infection in the absence of pIRS1. Con-
versely, infection of control cells with a pTRS1 deletion virus
(HCMVTRS1, described in reference 17; kindly provided by
AdamGeballe) provided a system to study specific roles for pIRS1,
while infection of shIRS1-HFs with HCMVTRS1 allowed us to
determine how the absence of both proteins affected HCMV rep-
lication. Importantly, in this system both pTRS1 and pIRS1 were
expressed from their native location in the viral genome under the
control of their endogenous promoters, allowing wild-type kinet-
ics and expression levels of the pTRS1 and pIRS1 proteins.
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Infection of shIRS1-HFs with wild-type HCMV resulted in a
significant reduction in pIRS1 expression at all times after infec-
tion (Fig. 1A). Importantly, pTRS1 expression was not affected by
the IRS1-specific shRNA. Consistent with previous reports show-
ing that pIRS1 is dispensable for HCMV replication (20), wild-
type virus replicated to equivalent titers in the two cell types de-
spite efficient depletion of pIRS1 in shIRS1-HFs (Fig. 1C). These
data also demonstrate that the IRS1-specific shRNA did not target
additional host or viral proteins necessary for HCMV replication.
Both wild-type and HCMVTRS1 replicated to similar levels fol-
lowing infection of control cells. However, HCMVTRS1 infec-
tion on shIRS1-HFs reduced viral replication by 2 orders of
magnitude (Fig. 1C). These data demonstrate that our system
confirms previous results showing that expression of either pTRS1
or pIRS1 is necessary for efficient HCMV replication.
We next examined viral protein expression after infection of
control HFs or shIRS1-HFs with wild-type or HCMVTRS1 vi-
rus. Similar levels of representative immediate early (IE), early,
and late proteins were expressed after infection of control cells or
shIRS1-HFs with wild-type virus. Viral proteins of each kinetic
class were also efficiently expressed after infection of control cells
with HCMVTRS1 virus (Fig. 1A and B); however, HCMV early
and late protein expression was reduced after infection of shIRS1-
HFs with the HCMVTRS1 virus (Fig. 1B). While the immediate
early protein IE1 was expressed equivalently in shIRS1-HFs and
control cells, we observed decreased expression of the early pro-
tein pUL44 and the late protein pp28 after infection of shIRS1-
HFs with HCMVTRS1 (Fig. 1B). Consistent with previous re-
sults (17), we conclude that the expression of either pTRS1 or
pIRS1 is necessary for the efficient expression of HCMV early and
late proteins.
pTRS1 or pIRS1 prevents PKR activation during HCMV in-
fection. pTRS1 and pIRS1 inhibit the antiviral kinase PKR in the
context of vaccinia virus infection and in transfected cells (16, 24,
56). To determine if pTRS1 and pIRS1 similarly limit PKR activa-
tion during HCMV infection, we measured PKR autophosphory-
lation and phosphorylation of the PKR substrate eIF2 after
infection of control cells or shIRS1-HFs with wild-type or
HCMVTRS1 virus. Infection with wild-type virus did not in-
duce PKR or eIF2 phosphorylation in either cell type (Fig. 2A),
demonstrating that the expression of pTRS1 is sufficient to limit
PKR activation. Similarly, neither PKR nor eIF2 was phosphor-
ylated in control cells infected with HCMVTRS1, showing that
pIRS1 expression is sufficient to suppress PKR. However, infec-
tion of shIRS1-HFs with HCMVTRS1 resulted in robust PKR
and eIF2 phosphorylation (Fig. 2A). Consistent with the inhibi-
tion of protein synthesis induced by eIF2 phosphorylation, we
FIG 1 Expression of either pTRS1or pIRS1 is necessary for efficient HCMV
replication. (A)Control cells (Scr) or shIRS1-HFswere infectedwithwild-type
HCMV at an MOI of 3. Cells were harvested at the indicated times and ana-
lyzed by Western blotting (n  3). (B) Control cells and shIRS1-HFs were
infected withHCMV lacking TRS1 (HCMVTRS1) at anMOI of 3. Cells were
harvested at the indicated times and analyzed byWestern blotting (n 3). (C)
Cells were infected as described for panel A, and the amount of virus in cell free
supernatants was measured by the TCID50 method (n 3).
FIG 2 HCMV pTRS1 or pIRS1 is necessary to antagonize PKR, maintain infected-cell protein synthesis, and inhibit stress granule formation. (A) Control cells
(Scr) or shIRS1-HFs (shIRS1) were infected with either wild-type virus orHCMVTRS1 at anMOI of 3. Cells were harvested at 24 h after infection and analyzed
byWestern blotting (n 3). Asterisks indicate nonspecific background bands. (B) Cells were infected as described for panel A, and the amount of radiolabeled
amino acids incorporated into acid-insoluble protein in 30 min was quantified at 24 h after infection (n 3; P	 0.05). Filled bars indicate wild-type infection,
and open bars indicate HCMVTRS1 infection. (C) Control cells or shIRS1-HFs were infected with HCMVTRS1, and the formation of G3BP1 puncta was
measured by indirect immunofluorescence at 24 h after infection. A representative image from one of three independent experiments is shown.
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observed an 80% decrease in the overall levels of protein synthesis
when shIRS1-HFs were infected with HCMVTRS1 (Fig. 2B).
These results demonstrate that the expression of either pTRS1 or
pIRS1 is necessary to antagonize PKR activation, limit eIF2
phosphorylation, and maintain protein synthesis in HCMV-in-
fected cells.
pTRS1 inhibits stress granule formation. eIF2 phosphory-
lation results in the redistribution of actively translating mRNAs
into cytoplasmic puncta termed stress granules (11, 57). While
stress granules do not form after infection with wild-type HCMV
(14), the increase in eIF2 phosphorylation after infection in the
absence of both pTRS1 and pIRS1 suggested that pTRS1 and
pIRS1 might limit stress granule formation during HCMV infec-
tion. In response to cellular stress, the G3BP1 protein localizes to
cytoplasmic stress granules (58); therefore, we used the formation
of G3BP1-positive cytoplasmic puncta as ameasure of stress gran-
ule formation.We found thatG3BP1 puncta do not accumulate in
control cells or shIRS1-HFs infectedwithwild-type virus (data not
shown). Similarly, few if anyG3BP1 puncta formed after infection
of control cells with theHCMVTRS1 virus (Fig. 2C). In contrast,
infection of shIRS1-HFs with HCMVTRS1 resulted in the accu-
mulation of G3BP1 puncta (Fig. 2C). Therefore, the expression of
either pTRS1 or pIRS1 is necessary to prevent stress granule for-
mation during HCMV infection.
To determine if pTRS1 was sufficient to prevent stress granule
formation, we measured the accumulation of stress granules in
cells transfected with a pTRS1 expression vector. Cells were trans-
fected with either a pTRS1 expression vector or a control vector
expressing GFP and then treated with arsenite to induce stress
granule accumulation.G3BP1puncta readily accumulated in con-
trol cells expressing GFP. However, very few G3BP1-positive
granules were found in cells expressing pTRS1 (Fig. 3A). Interest-
ingly, arsenite induces stress granule formation through activa-
tion of the eIF2 kinase HRI (59), suggesting that pTRS1 could
inhibit stress granule formation induced by eIF2 kinases other
than PKR. To confirm that PKR was dispensable for arsenite-
induced stress granule formation, we measured the formation of
G3BP1 puncta after arsenite treatment in cells lacking PKR ex-
pression. The PKR gene in these cells was mutated using CRISPR/
Cas9-mediated mutagenesis (56). Arsenite readily induced stress
granule formation in PKR-deficient cells, and this induction was
inhibited by pTRS1 expression (Fig. 3B). In order to measure the
effect of pTRS1 expression on stress granule formation, we deter-
mined the number of cells containing stress granules among cells
expressing pTRS1 orGFP. Stress granules formed in90%of cells
expressing GFP regardless of GFP expression levels (Fig. 3C, top
panel). In contrast, a limited number of stress granule-positive
cells (	45%) were found in cells expressing low levels of pTRS1.
Higher levels of pTRS1 expression were sufficient to completely
inhibit stress granule formation (Fig. 3C, bottompanel). Together
our results demonstrate that pTRS1 is necessary and sufficient to
prevent stress granule formation and suggest that pTRS1 also pre-
vents stress granule formation induced by additional eIF2 ki-
nases.
PKRdepletionprevents eIF2phosphorylation and restores
HCMV protein expression and replication in the absence of
pTRS1 and pIRS1. The increase in eIF2 and PKR phosphoryla-
tion observed in the absence of pTRS1 and pIRS1 during infection
FIG 3 pTRS1 is sufficient to inhibit stress granule formation. (A) HeLa cells were transfected with a GFP or pTRS1 expression vector. Twenty-four hours after
transfection, cells were treated with sodium arsenite (0.5 mM) for 1 h, and G3BP1 punctum formation was measured by indirect immunofluorescence. (B)
PKR-deficient HeLa cells were transfected with a GFP or pTRS1 expression vector. Cells were treated with arsenite as described for panel A and analyzed by
indirect immunofluorescence as above. (C) Western blotting was used to measure PKR expression in PKR-deficient HeLa cells. PKR-deficient cells were
transfected and treated as described for panel A. The presence ofG3BP1-positive puncta in transfected cells was determined by indirect immunofluorescence. The
range of transgene expression was divided into quartiles (1 to 25% of maximum, 26 to 50% of maximum, etc.), and the results are shown as the percentage of
GFP-expressing (top panel) or pTRS1-expressing (bottom panel) cells containing two or more G3BP1 puncta.
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suggested that stress granulesmight formas a consequence of PKR
activation. To determine if PKR was necessary for stress granule
formation during infection, we measured G3BP1 punctum for-
mation in PKR-depleted cells in the absence of pTRS1 and pIRS1.
We found that PKR depletion reversed stress granule accumula-
tion in shIRS1-HFs infected with HCMVTRS1 (Fig. 4A). Thus,
pTRS1 and pIRS1 expression counteracted PKR-induced stress
granule formation during HCMV infection. In addition, PKR de-
pletion increased the expression of HCMV early and late proteins
and prevented eIF2 phosphorylation (Fig. 4B). The increased
expression of viral proteins after PKRdepletion correlatedwith an
increase in the overall levels of protein synthesis in infected cells
(Fig. 4C). Consistent with the increase in protein synthesis, PKR
depletion partially rescued HCMVTRS1 replication in shIRS1-
HFs (Fig. 4D). We conclude that antagonism of PKR by pTRS1
and/or pIRS1 is necessary for efficient viral protein synthesis and
replication.
The pTRS1 PKR binding domain is required during infec-
tion to antagonize PKR.As discussed above, several pTRS1 func-
tional domains have been described outside the context of HCMV
infection (18, 21) including a PKR binding domain in the carbox-
yl-terminal 116 amino acids of pTRS1 (19). As our system allows
for the efficient reconstitution and propagation of pTRS1 mutant
viruses, we next determined the role of the pTRS1 PKR binding
domain in HCMV replication. We first generated a mutant virus
lacking the pTRS1 PKR binding domain (HCMVPDB) (Fig.
5A). We used BAC-mediated recombineering to delete the final
116 amino acids of pTRS1, which contains the previously de-
scribed PKR binding domain (19), and fuse a FLAG epitope to the
pTRS1 carboxyl terminus to allow us tomonitor expression of the
mutant pTRS1 protein. This mutant expresses pTRS1 from its
native location in the viral genome under the control of its endog-
enous promoter allowing for wild-type kinetics and levels of
pTRS1 expression. Infectious virus was recovered after electropo-
ration of the mutant genome into primary human fibroblasts,
indicating that the HCMVPDB virus was viable. The truncated
pTRS1 was expressed throughout infection, although to slightly
lower levels than wild-type pTRS1 (Fig. 5B). In addition, the
pTRS1 mutant displayed diffuse cytoplasmic localization, similar
to wild-type pTRS1 (data not shown).
We then measured the replication of the HCMVPDB virus
over a single round of virus replication. HCMVPDB replicated
to lower titers than HCMVTRS1 on control cells, and virus rep-
lication was further reduced 10-fold in the absence of pIRS1
FIG 4 PKR inhibits viral protein synthesis and induces stress granule formation in the absence of pTRS1 and pIRS1. (A) shIRS1-HFs were transfected with
scrambled or PKR-specific siRNAs prior to infection with HCMVTRS1. The formation of G3BP1 (
) puncta was monitored by indirect immunofluorescence
at 24 h after infection. A representative image from one of three independent experiments is shown. (B) shIRS1-HFs were transfected with scrambled (scr) or
PKR-specific (PKR) siRNAs prior to infectionwithHCMVTRS1. Expression of the indicated proteins wasmeasured byWestern blotting at 96 h after infection,
except for eIF2-P and total eIF2, which were measured at 24 h after infection (n 3). (C) Cells stably expressing scrambled (Scr) or pIRS1-specific (IRS1)
shRNAs were transfected with scrambled (scr) or PKR-specific (PKR) siRNAs and then infected with HCMVTRS1. The amount of radiolabeled amino acids
incorporated into acid-insoluble protein in 30minwas quantified at 24 h after infection (n 3). (D) Cells were treated and infected as described for panel C. The
amount of virus in the culture supernatants at 96 h after infection was determined by the TCID50 method (n 3).
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(Fig. 5C). While the HCMV early protein pUL44 and late protein
pp28 were expressed in control cells during HCMVPDB infec-
tion, the expression of both viral proteins was significantly de-
creased in shIRS1-HFs (Fig. 6A). Interestingly, the expression of
the mutant pTRS1 protein itself was also significantly reduced in
pIRS1-depleted cells. To determine if PKR activation might ac-
count for diminished viral protein expression, we measured PKR
and eIF2 phosphorylation after infection of control or shIRS1-
HFswith theHCMVPDB virus.We found no increase in PKR or
eIF2 phosphorylation after infection of control cells with
HCMVPDB (Fig. 6B), indicating that truncation of the pTRS1
carboxyl terminus did not result in PKR activation in the presence
of pIRS1. However, the HCMVPDB virus induced robust PKR
and eIF2 phosphorylation when pIRS1 was depleted (Fig. 6B),
with a concomitant reduction in the overall levels of protein syn-
thesis (Fig. 6C). In addition, HCMVPDB infection induced
FIG 5 The pTRS1 PKR binding domain is required for efficient virus replication. (A) Cartoon showing the region of pTRS1 deleted in the HCMVPBD virus.
(B) Western blot showing expression of pTRS1 after infection with wild-type HCMV or HCMVPBD virus at 72 h after infection. (C) Control HFs (scr; filled
bars) or shIRS1-HFs (open bars) were infected with HCMVTRS1 or HCMVPBD virus at an MOI of 1, and the amount of cell-free virus in the culture
supernatants was quantified by the TCID50 method (n 3).
FIG 6 The pTRS1 PKR binding domain is necessary to antagonize PKR in the absence of pIRS1. (A) Control HFs (Scr) or shIRS1-HFs (shIRS1) were infected
with theHCMVPBD virus at anMOI of 1. Cells were harvested at the indicated times after infection, and the expression of the indicated proteins wasmeasured
by Western blotting (n 3). (B) Control HFs or shIRS1-HFs were infected with the indicated virus as described for panel A. Cells were harvested at 24 h after
infection and analyzed byWestern blotting (n 3). (C) Control HFs (filled bars) or shIRS1-HFs (open bars) were infected with HCMVTRS1 or HCMVPBD
virus, and the amount of radiolabeled amino acids incorporated into acid-insoluble protein in 30 min was quantified 24 h after infection (n 3). (D) Control
HFs or shIRS1-HFs were infected with HCMVPBD, and the presence of G3BP1 puncta was determined by indirect immunofluorescence 24 h after infection.
Representative images from one of three independent experiments are shown. (E) Cells were transfected with a pTRS1PBD expression vector and treated and
analyzed as described for Fig. 3. Representative results from one of three independent experiments are shown.
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stress granule accumulation in the absence of pIRS1, but not in
control cells (Fig. 6D), and expression of the pTRS1PBDprotein
was not sufficient to prevent arsenite-induced stress granule for-
mation in PKR-deficient cells (Fig. 6E). We conclude that the
carboxyl terminus of pTRS1 is required for efficient virus replica-
tion, even in the presence of pIRS1. Furthermore, our results sug-
gest that the pTRS1 PKR binding domain is necessary to antago-
nize PKR during HCMV infection.
DISCUSSION
In this study, we developed a novel system for the study of pTRS1
and its functional domains in the context of viral infection. Using
this system, we confirmed the results of a previous study (17) by
showing that expression of either pTRS1 or pIRS1 is necessary for
efficient HCMV replication and protein expression. We also
found that in the absence of pTRS1 and pIRS1, HCMV infection
activates the antiviral kinase PKR. We further show that antago-
nism of PKR by pTRS1 or pIRS1 is critical for ongoing protein
synthesis during HCMV infection, as PKR depletion prevented
eIF2 phosphorylation and the shutoff of protein synthesis in the
absence of pTRS1 and pIRS1. In addition, depletion of PKR re-
stored the expression of HCMV proteins and rescued virus repli-
cation, in the absence of pTRS1 and pIRS1. We also identified a
novel role for pTRS1 as an inhibitor of stress granule formation.
Expression of either pTRS1 or pIRS1 was sufficient to suppress
PKR-dependent stress granule accumulation during HCMV in-
fection, and pTRS1 alone was sufficient to prevent PKR-indepen-
dent stress granule formation in transfected cells. The ability of
pTRS1 to antagonize PKR and prevent stress granule formation
during infection required the previously identified PKR binding
domain, suggesting that a direct interaction between pTRS1 and
PKR is critical for efficient virus replication.
Our data demonstrate that pTRS1 and pIRS1 inhibit PKR ac-
tivation during HCMV infection and that PKR antagonism is a
critical function of pTRS1 and pIRS1, required for efficient viral
replication. PKR autophosphorylation and substrate phosphory-
lation were increased in the absence of both pTRS1 and pIRS1
during infection (Fig. 2A), and overall levels of protein synthesis
were greatly reduced (Fig. 2B). As a result, virus replication and
HCMV protein synthesis were significantly impaired (Fig. 1B and
C). Depleting PKR prior to infection rescued HCMV replication
(Fig. 4D) and restored viral protein expression (Fig. 4B) and over-
all levels of protein synthesis in the absence of pTRS1 and pIRS1
(Fig. 4C). Therefore, our data show that inhibition of PKR is a
critical function of pTRS1 and pIRS1 during HCMV infection.
Our data also suggest pTRS1 may have additional roles in
HCMV replication. The HCMVPDB virus replicated less effi-
ciently than wild-type virus even in the presence of pIRS1 (Fig.
5C). The HCMVPDB mutant did not induce PKR or eIF2
phosphorylation or stimulate stress granule formation when
pIRS1 was present (Fig. 6B and D), and thus the truncated pTRS1
does not appear to act in a dominant negative manner toward
pIRS1, at least in regard to PKR inhibition. These results suggest
that pTRS1 may have additional roles in HCMV replication. Pre-
vious studies found that replication of an HCMV pTRS1/pIRS1
double mutant virus was rescued by the vaccinia virus E3L pro-
tein, a known PKR antagonist (17). However, E3L also suppresses
additional aspects of the antiviral response (60–65). Perhaps
pTRS1 shares these PKR-independent activities with E3L. The
truncation could also impact the ability of pTRS1 to facilitate
packaging of viral DNA into nascent nucleocapsids (41) or per-
haps limit the ability of pTRS1 to regulate autophagy (38, 39) or
transactivate viral gene expression (40). Alternatively, the trun-
cated pTRS1 isoform might partially inhibit pIRS1 function, re-
sulting in low levels of PKR activation that are sufficient to limit
viral mRNA translation. Additional studies in primary human
cells completely devoid of PKR expression will be needed to de-
termine what, if any, role pTRS1 plays in HCMV replication in
addition to inhibiting PKR activation.
We also identified a novel role for pTRS1 in preventing stress
granule formation. Previous studies found that stress granules do
not form duringHCMV infection (14, 56), despite the presence of
dsRNAs (17). Our results provide a molecular mechanism for the
lack of stress granules during HCMV infection, namely, the an-
tagonism of PKR by pTRS1 and pIRS1. Stress granules did not
form in infected cells expressing either pTRS1 or pIRS1; however,
the absence of both proteins from infected cells triggered robust
stress granule accumulation (Fig. 2C). Thus, expression of either
pTRS1 or pIRS1 was necessary to prevent stress granule accumu-
lation duringHCMV infection. PKRdepletion limited stress gran-
ule accumulation in infected cells in the absence of pTRS1 and
pIRS1 (Fig. 4A), demonstrating that PKR activation triggers stress
granule formation during HCMV infection. In addition, expres-
sion of pTRS1 outside the context of infection was sufficient to
prevent stress granule accumulation in response to arsenite treat-
ment (Fig. 3A), showing that additional viral proteins are not
required for this activity. pTRS1 also blocked stress granule accu-
mulation in response to arsenite treatment in PKR-deficient cells
(Fig. 3B and C), suggesting that pTRS1 can prevent stress granule
accumulation independent of its ability to antagonize PKR. Stress
granules inhibit virus replication by sequestering viral RNAs and
preventing their translation (12, 13, 57). While additional studies
using depletion of specific stress granule components will be re-
quired to understand the impact of stress granule accumulation
on HCMV infection, our results suggest that stress granules could
similarly regulate HCMV protein synthesis.
Our data also provide new insight into the pTRS1 functional
domains necessary for PKR inhibition during HCMV infection.
The carboxyl-terminal 116 amino acids of pTRS1 contains a PKR
binding domain that is necessary to complement growth in a vac-
cinia virus mutant lacking its major PKR antagonist, the E3L pro-
tein (18). Deletion of the pTRS1 PKR binding domain resulted in
PKR activation, decreased viral protein expression, and limited
virus replication in the absence of pIRS1 (Fig. 6). It was previously
suggested that pTRS1 inhibits PKR in part by competingwith PKR
for binding to dsRNA (21). Our finding that PKR was autophos-
phorylated after infection with the HCMVPBD virus does not
contradict this conclusion but rather suggests that during HCMV
infection the ability of pTRS1 to bind dsRNA is not sufficient to
antagonize PKR. However, we cannot rule out that these muta-
tions alter pTRS1 folding to abrogate its function. Structural anal-
ysis of pTRS1 and PKR will likely provide a better understanding
of how these domains contribute to PKR inhibition. Nevertheless,
in light of the failure of theHCMVPBD pTRS1mutant to antag-
onize PKR, it seems likely that pTRS1 binding to PKR is critical for
PKR inhibition during HCMV infection. Confirmation of this
hypothesis will require careful mapping of pTRS1 point mutants
that specifically disrupt pTRS1 binding to PKR and the analysis of
recombinant viruses carrying these mutations.
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